Niraparib particles and uses thereof
Niraparib particles with high SSA and controlled size improve dissolution rates, addressing poor solubility issues and enhancing drug absorption, reducing dosing frequency and side effects.
Patent Information
- Application Number
- JP2024524405
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-11-10
- Filing Date
- 2022-11-08
- Publication Date
- 2024-11-21
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Poor water solubility and dissolution rates limit the in vivo bioavailability of many drugs, necessitating methods to enhance their dissolution rates.
Development of niraparib particles with a high specific surface area (SSA) and controlled particle size distribution, free of certain excipients, to improve dissolution and bioavailability.
The high SSA and controlled particle size of niraparib particles significantly enhance dissolution rates, facilitating better drug absorption and reducing systemic concentrations, thus potentially lowering dosing frequency and side effects.
Smart Images

Figure 2024543318000005 
Figure 2024543318000006 
Figure 2024543318000007
Abstract
Description
[Technical field]
[0001] cross reference This application claims priority to U.S. Provisional Patent Application No. 63 / 277,780, filed November 10, 2021, which is incorporated by reference in its entirety. [Background technology]
[0002] Dissolution rate is the main parameter in determining the rate and extent of drug absorption and bioavailability.Poor water solubility and poor in vivo dissolution are limiting factors for the in vivo bioavailability of many drugs.Therefore, in vitro dissolution rate is recognized as an important factor in drug development, and there is a need for methods and compositions for enhancing the dissolution rate of poorly soluble drugs. Summary of the Invention
[0003] In one aspect, the disclosure provides a composition comprising particles comprising at least 95% by weight of niraparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 5 mm. 2 In another embodiment, the particles have a specific surface area (SSA) of 5 m 2 / g~about 50m 2 In a further embodiment, the particles have an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter. In one embodiment, the particles have an SSA of about 0.020 g / cm 3 ~about 0.500g / cm 3 In another embodiment, the particles have an average bulk density (not tapped density) of about 0.050 g / cm 3 ~Approx. 0.600g / cm 3 The average tap density is
[0004] In one embodiment, the particles are uncoated and are free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides, which are composed of mono-, di-, and triglycerides and mono- and diesters of polyethylene glycol. In another embodiment, the composition comprises a suspension further comprising a pharma- ceutically acceptable liquid carrier. In one embodiment, the suspension is aerosolized and the mass median aerodynamic diameter (MMAD) of the aerosolized droplets of the suspension can be any suitable diameter for use, such as about 0.5 μm to about 6 μm in diameter. In another embodiment, the composition is a dry powder composition and the dry powder composition is aerosolized and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as about 0.5 μm to about 6 μm in diameter. In one embodiment, the pharma- ceutically acceptable salt of niraparib comprises niraparib tosylate monohydrate.
[0005] In another aspect, the present disclosure provides a method for treating a tumor, comprising administering to a subject having a tumor an amount of a composition of any embodiment or combination of embodiments of the present disclosure effective to treat the tumor. (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), or a combination thereof, and at least one solute, including niraparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a vessel defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into a pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2 mm to 20 mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20 μm to 125 μm; (c) contacting the atomized droplets with a compressed fluid to cause removal of solvent from the atomized droplets to produce niraparib particles comprising at least 95% niraparib or a pharma- ceutically acceptable salt thereof, wherein the niraparib particles have a molecular weight of at least 5 mm 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method is provided wherein steps (a), (b) and (c) are carried out under the supercritical temperature and pressure of the compressed fluid. [Brief description of the drawings]
[0006] [Figure 1] (A) Scanning electron microscopy micrographs of crude niraparib at 500x and (B) crude niraparib at 2000x. [Diagram 2] Scanning electron microscopy micrographs of (A) Niraparib-SC1 1000x and (B) Niraparib-SC1 5000x. [Diagram 3] Scanning electron microscopy micrographs of (A) Niraparib SC2 1000x, (B) Niraparib SC2 5000x. [Figure 4] Scanning electron microscopy micrographs of (A) Niraparib SC3 1000x and (B) Niraparib SC3 5000x. [Diagram 5] Scanning electron microscopy micrographs of (A) Niraparib SC4 1000x and (B) Niraparib SC4 5000x. [Figure 6] Powder X-ray diffraction patterns of niraparib experimental SC1-SC4 compared with raw niraparib [Figure 7] Graph showing dissolution of unprocessed Niraparib (raw) or processed Niraparib particles in 900 mL of 10% MeOH-water at 50 rpm. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0007] All cited references are incorporated herein by reference in their entirety. As used herein, the singular forms "a," "an," and "the" include plural references unless the context clearly dictates otherwise. All embodiments of any aspect of the present disclosure can be used in combination unless the context clearly dictates otherwise.
[0008] As used herein, "about" means + / - 5% of the specified numerical value.
[0009] In one aspect, the disclosure provides a composition comprising particles comprising at least 95% by weight of niraparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 5 mm. 2 / g. Such particles are referred to herein as "niraparib particles."
[0010] As used herein, "niraparib" includes any ionized state of niraparib, including base, acid, and neutral states.
[0011] [ka] Chemical name of Niraparib: (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
[0012] "Niraparib particles" refers to particles of niraparib, or a pharma- ceutically acceptable salt thereof, and does not include additional excipients. Niraparib particles are different from "particles containing niraparib", which are particles that include niraparib and at least one additional excipient. The niraparib particles of the present disclosure do not include polymeric, waxy, or protein excipients, and are not embedded, enclosed, enclosed, or encapsulated in solid excipients. However, the niraparib particles of the present disclosure may include impurities and by-products that are typically found during the preparation of niraparib. Nevertheless, the niraparib particles include at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100% niraparib, or a pharma- ceutically acceptable salt thereof, meaning that the niraparib particles consist of or essentially consist of substantially pure niraparib or a pharma- ceutically acceptable salt of niraparib.
[0013] As used herein, "specific surface area" is the total surface area of niraparib particles per unit of niraparib mass as measured by the Brunauer-Emmett-Teller ("BET") isotherm (i.e.: BET SSA). As will be understood by those skilled in the art, the SSA is determined on a per gram basis and takes into account both aggregated and non-aggregated niraparib particles in the composition. The BET specific surface area test procedure is an official method contained in both the United States Pharmacopoeia and the European Pharmacopoeia. Niraparib particles have a specific surface area of at least 5 m 2 In various further embodiments, the niraparib particles have a specific surface area (SSA) of at least 6 m 2 / g, 7m 2 / g, 8m 2 / g, 9m 2 / g, 10m 2 / g, 11m 2 / g, 12m 2 / g, 13m 2 / g, 14m 2 / g, 15m 2 / g, 16m 2 / g, 17m 2 / g, 18m 2 / g, 19m 2 / g, 20m2 / g, 21m 2 / g, 22m 2 / g, 23m 2 / g, or 24m 2 / g SSA.
[0014] In a further embodiment, the niraparib particles are 2 / g~about 50m 2 / g, approx. 6m 2 / g~about 50m 2 / g, about 7m 2 / g~about 50m 2 / g, approx. 8m 2 / g~about 50m 2 / g, approx. 9m 2 / g~about 50m 2 / g, approx. 10m 2 / g~about 50m 2 / g, approx. 11m 2 / g~about 50m 2 / g, approx. 12m 2 / g~about 50m 2 / g, approx. 13m 2 / g~about 50m 2 / g, approx. 14m 2 / g~about 50m 2 / g, approx. 15m 2 / g~about 50m 2 / g, approx. 16m 2 / g~about 50m 2 / g, approx. 17m 2 / g~about 50m 2 / g, approx. 18m 2 / g~about 50m 2 / g, approx. 19m 2 / g~about 50m 2 / g, about 20m 2 / g~about 50m 2 / g, approx. 21m 2 / g~about 50m 2 / g, approx. 22m 2 / g~about 50m 2 / g, approx. 23m 2 / g~about 50m 2 / g, approx. 24m 2 / g~about 50m 2 / g, 5m 2 / g~about 45m 2 / g, approx. 6m2 / g ~ about 45 m 2 / g, about 7 m 2 / g ~ about 45 m 2 / g, about 8 m 2 / g ~ about 45 m 2 / g, about 9 m 2 / g ~ about 45 m 2 / g, about 10 m 2 / g ~ about 45 m 2 / g, about 11 m 2 / g ~ about 45 m 2 / g, about 12 m 2 / g ~ about 45 m 2 / g, about 13 m 2 / g ~ about 45 m 2 / g, about 14 m 2 / g ~ about 45 m 2 / g, about 15 m 2 / g ~ about 45 m 2 / g, about 16 m 2 / g ~ about 45 m 2 / g, about 17 m 2 / g ~ about 45 m 2 / g, about 18 m 2 / g ~ about 45 m 2 / g, about 19 m 2 / g ~ about 45 m 2 / g, about 20 m 2 / g ~ about 45 m 2 / g, about 21 m 2 / g ~ about 45 m 2 / g, about 22 m 2 / g ~ about 45 m 2 / g, about 23 m 2 / g ~ about 45 m 2 / g, about 24 m 2 / g ~ about 45 m 2 / g, 5 m 2 / g ~ about 40 m 2 / g, about 6 m 2 / g ~ about 40 m 2 / g, about 7 m 2 / g ~ about 40 m 2 / g, about 8 m 2 / g ~ about 40 m 2 / g, about 9 m 2 / g ~ about 40 m 2 / g, about 10 m 2 / g ~ about 40 m 2 / g, about 11 m 2 2 / g ~ about 40 m 2 / g, about 12 m 2 / g ~ about 40 m 2 / g, about 13 m 2 / g ~ about 40 m 2 / g, about 14 m 2 / g ~ about 40 m 2 / g, about 15 m 2 / g ~ about 40 m 2 / g, about 16 m 2 / g ~ about 40 m 2 / g, about 17 m 2 / g ~ about 40 m 2 / g, about 18 m 2 / g ~ about 40 m 2 / g, about 19 m 2 / g ~ about 40 m 2 / g, about 20 m 2 / g ~ about 40 m 2 / g, about 21 m 2 / g ~ about 40 m 2 / g, about 22 m 2 / g ~ about 40 m 2 / g, about 23 m 2 / g ~ about 40 m 2 / g, about 24 m 2 / g ~ about 40 m 2 / g, 5 m 2 / g ~ about 35 m 2 / g, about 6 m 2 / g ~ about 35 m 2 / g, about 7 m 2 / g ~ about 35 m 2 / g, about 8 m 2 / g ~ about 35 m 2 / g, about 9 m 2 / g ~ about 35 m 2 / g, about 10 m 2 / g ~ about 35 m 2 / g, about 11 m 2 / g ~ about 35 m 2 / g, about 12 m 2 / g ~ about 35 m 2 / g, about 13 m 2 / g ~ about 35 m 2 / g, about 14 m 2 / g ~ about 35 m 2 / g, about 15 m 2 / g ~ about 35 m 2 / g, about 16 m 2 / g ~ about 35 m2 / g, about 17 m 2 / g to about 35 m 2 / g, about 18 m 2 / g to about 35 m 2 / g, about 19 m 2 / g to about 35 m 2 / g, about 20 m 2 / g to about 35 m 2 / g, about 21 m 2 / g to about 35 m 2 / g, about 22 m 2 / g to about 35 m 2 / g, about 23 m 2 / g to about 35 m 2 / g, about 24 m 2 / g to about 35 m 2 / g, 5 m 2 / g to about 30 m 2 / g, about 6 m 2 / g to about 30 m 2 / g, about 7 m 2 / g to about 30 m 2 / g, about 8 m 2 / g to about 30 m 2 / g, about 9 m 2 / g to about 30 m 2 / g, about 10 m 2 / g to about 30 m 2 / g, about 11 m 2 / g to about 30 m 2 / g, about 12 m 2 / g to about 30 m 2 / g, about 13 m 2 / g to about 30 m 2 / g, about 14 m 2 / g to about 30 m 2 / g, about 15 m 2 / g to about 30 m 2 / g, about 16 m 2 / g to about 30 m 2 / g, about 17 m 2 / g to about 30 m 2 / g, about 18 m 2 / g to about 30 m 2 / g, about 19 m 2 / g to about 30 m 2 / g, about 20 m 2 / g to about 30 m 2 / g, about 21 m 2 / g to about 30 m2 / g, approx. 22m 2 / g ~ approx. 30m 2 / g, approx. 23m 2 / g ~ approx. 30m 2 / g, or about 24m 2 / g ~ approx. 30m 2 / g SSA.
[0015] In one embodiment, the niraparib particles have a mean particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter. In some embodiments, the niraparib particles have a mean particle size by volume distribution of about 1 micron to about 6 microns in diameter, or about 2 microns to about 6 microns in diameter. The niraparib particles are in a size range that is unlikely to be transported out of the tumor by the systemic circulation, and further benefit from a high specific surface area to facilitate drug solubilization and release.
[0016] In one embodiment, the niraparib particles have a mass of about 0.020 g / cm 3 ~about 0.500g / cm 3 In various further embodiments, the niraparib particles have an average bulk density (not tapped density) of about 0.020 g / cm 3 ~Approx. 0.475g / cm 3 , about 0.020g / cm 3 ~Approx. 0.450g / cm 3 , about 0.020g / cm 3 ~Approx. 0.425g / cm 3 , about 0.020g / cm 3 ~Approx. 0.400g / cm 3 , about 0.020g / cm 3 ~Approx. 0.375g / cm 3 , about 0.020g / cm 3 ~Approx. 0.350g / cm 3 , about 0.020g / cm 3 ~Approx. 0.325g / cm 3 , about 0.020g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm 3 ~Approx. 0.275g / cm 3 , about 0.020g / cm3 ~ about 0.250 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.225 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.200 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.175 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.150 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.125 g / cm 3 、 about 0.020 g / cm 3 ~ about 0.100 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.475 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.450 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.425 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.400 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.375 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.350 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.325 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.300 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.275 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.250 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.225 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.200 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.175 g / cm 3 、 about 0.040 g / cm 3 ~ about 0.150 g / cm 3, about 0.040g / cm 3 ~Approx. 0.125g / cm 3 , about 0.040g / cm 3 ~Approx. 0.100g / cm 3 , about 0.060g / cm 3 ~Approx. 0.475g / cm 3 , about 0.060g / cm 3 ~Approx. 0.450g / cm 3 , about 0.060g / cm 3 ~Approx. 0.425g / cm 3 , about 0.060g / cm 3 ~Approx. 0.400g / cm 3 , about 0.060g / cm 3 ~Approx. 0.375g / cm 3 , about 0.060g / cm 3 ~Approx. 0.350g / cm 3 , about 0.060g / cm 3 ~Approx. 0.325g / cm 3 , about 0.060g / cm 3 ~Approx. 0.300g / cm 3 , about 0.060g / cm 3 ~Approx. 0.275g / cm 3 , about 0.060g / cm 3 ~Approx. 0.250g / cm 3 , about 0.060g / cm 3 ~Approx. 0.225g / cm 3 , about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , about 0.060g / cm 3 ~Approx. 0.125g / cm 3 , or about 0.060 g / cm 3 ~Approx. 0.100g / cm 3 The average bulk density (not tapped density) is
[0017] In another embodiment, the niraparib particles have a mass of about 0.050 g / cm 3 ~Approx. 0.600g / cm 3In various further embodiments, the niraparib particles have an average tap density of about 0.050 g / cm 3 ~Approx. 0.575g / cm 3 , about 0.050g / cm 3 ~Approx. 0.550g / cm 3 , about 0.050g / cm 3 ~Approx. 0.525g / cm 3 , about 0.050g / cm 3 ~about 0.500g / cm 3 , about 0.050g / cm 3 ~Approx. 0.475g / cm 3 , about 0.050g / cm 3 ~Approx. 0.450g / cm 3 , about 0.050g / cm 3 ~Approx. 0.425g / cm 3 , about 0.050g / cm 3 ~Approx. 0.400g / cm 3 , about 0.050g / cm 3 ~Approx. 0.375g / cm 3 , about 0.050g / cm 3 ~Approx. 0.350g / cm 3 , about 0.050g / cm 3 ~Approx. 0.325g / cm 3 , about 0.050g / cm 3 ~Approx. 0.300g / cm 3 , about 0.050g / cm 3 ~Approx. 0.275g / cm 3 , about 0.050g / cm 3 ~Approx. 0.250g / cm 3 , about 0.050g / cm 3 ~Approx. 0.225g / cm 3 , about 0.050g / cm 3 ~Approx. 0.200g / cm 3 , about 0.050g / cm 3 ~Approx. 0.175g / cm 3 , about 0.050g / cm 3 ~Approx. 0.150g / cm 3 , about 0.050g / cm 3 ~Approx. 0.125g / cm 3 , about 0.075g / cm 3 ~Approx. 0.575g / cm 3, about 0.075 g / cm 3 ~ about 0.550 g / cm 3 , about 0.075 g / cm 3 ~ about 0.525 g / cm 3 , about 0.075 g / cm 3 ~ about 0.500 g / cm 3 , about 0.075 g / cm 3 ~ about 0.475 g / cm 3 , about 0.075 g / cm 3 ~ about 0.450 g / cm 3 , about 0.075 g / cm 3 ~ about 0.425 g / cm 3 , about 0.075 g / cm 3 ~ about 0.400 g / cm 3 , about 0.075 g / cm 3 ~ about 0.375 g / cm 3 , about 0.075 g / cm 3 ~ about 0.350 g / cm 3 , about 0.075 g / cm 3 ~ about 0.325 g / cm 3 , about 0.075 g / cm 3 ~ about 0.300 g / cm 3 , about 0.075 g / cm 3 ~ about 0.275 g / cm 3 , about 0.075 g / cm 3 ~ about 0.250 g / cm 3 , about 0.075 g / cm 3 ~ about 0.225 g / cm 3 , about 0.075 g / cm 3 ~ about 0.200 g / cm 3 , about 0.075 g / cm 3 ~ about 0.175 g / cm 3 , about 0.075 g / cm 3 ~ about 0.150 g / cm 3 , about 0.075 g / cm 3 ~ about 0.125 g / cm 3 , about 0.100 g / cm 3 ~ about 0.575 g / cm 3 , about 0.100 g / cm 3 ~ about 0.550 g / cm 3 , about 0.100 g / cm 3 ~ about 0.525 g / cm3 , about 0.100g / cm 3 ~about 0.500g / cm 3 , about 0.100g / cm 3 ~Approx. 0.475g / cm 3 , about 0.100g / cm 3 ~Approx. 0.450g / cm 3 , about 0.100g / cm 3 ~Approx. 0.425g / cm 3 , about 0.100g / cm 3 ~Approx. 0.400g / cm 3 , about 0.100g / cm 3 ~Approx. 0.375g / cm 3 , about 0.100g / cm 3 ~Approx. 0.350g / cm 3 , about 0.100g / cm 3 ~Approx. 0.325g / cm 3 , about 0.100g / cm 3 ~Approx. 0.300g / cm 3 , about 0.100g / cm 3 ~Approx. 0.275g / cm 3 , about 0.100g / cm 3 ~Approx. 0.250g / cm 3 , about 0.100g / cm 3 ~Approx. 0.225g / cm 3 , about 0.100g / cm 3 ~Approx. 0.200g / cm 3 , about 0.100g / cm 3 ~Approx. 0.175g / cm 3 , about 0.100g / cm 3 ~Approx. 0.150g / cm 3 , or about 0.100 g / cm 3 ~Approx. 0.125g / cm 3 The average tap density is
[0018] As used herein, the bulk density (not tapped density) of a particle is the ratio of mass to volume (including interparticle excluded volume) of an untapped powder sample.
[0019] As used herein, tap density of a particle is obtained by mechanically tapping a graduated cylinder containing a sample until no significant further change in volume is observed.
[0020] The increased specific surface area and decreased bulk density of niraparib particles results in a significant increase in dissolution rate, for example, compared to raw or milled niraparib products. Dissolution occurs only at the solid / liquid interface. Therefore, a large specific surface area increases the dissolution rate due to the large number of molecules on the surface of the particles in contact with the dissolution medium. Bulk density takes into account the powder's macrostructure and interparticle space. Parameters that contribute to bulk density include particle size distribution, particle shape, and particle-to-particle affinity (i.e., cohesion). The lower the bulk density of the powder, the faster the dissolution rate. This is due to the ability of the dissolution medium to more easily penetrate the gaps or interparticle spaces and make greater contact with the surface of the particles. This provides a significant improvement for the use of niraparib particles disclosed herein, for example, in tumor treatment.
[0021] In any of these various embodiments, the niraparib particles may, for example, have at least 5×10 per niraparib particle. -15 gram of niraparib or a pharma- ceutically acceptable salt thereof, or about 1 x 10 per niraparib particle -8 ~Approx. 5×10 -15 grams of niraparib, or a pharma- ceutical acceptable salt thereof.
[0022] In one embodiment, the particles are uncoated and are free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides, which are composed of mono-, di-, and triglycerides and mono- and diesters of polyethylene glycol.
[0023] In further embodiments, the composition comprises a liquid suspension further comprising a pharma- ceutically acceptable liquid carrier. The suspension of the present disclosure comprises niraparib particles and a liquid carrier. The liquid carrier may be aqueous or non-aqueous. Even if the niraparib particles do not comprise additional excipients, the liquid carrier of the suspension may comprise water or a non-aqueous liquid, and optionally one or more excipients selected from the group consisting of a buffer, an isotonicity agent, a preservative, a demulcent, a viscosity modifier, an osmotic agent, a surfactant, an antioxidant, an alkalinizing agent, an acidifying agent, an antifoaming agent, and a coloring agent. For example, the suspension may comprise niraparib particles, water, a buffer, and a salt. In some cases, it may further comprise a surfactant. In some embodiments, the suspension consists essentially of or consists of water, niraparib particles suspended in water, and a buffer. The suspension may further comprise an osmotic salt. In another example, the suspension may comprise niraparib particles and a non-aqueous liquid, such as a liquefied gas propellant. Examples of liquefied gas propellants include, but are not limited to, hydrofluoroalkanes (HFAs). Examples of other non-aqueous liquids include, but are not limited to, mineral oil, vegetable oil, glycerin, polyethylene glycol, poloxamers that are liquid at room temperature (e.g., poloxamer 124), and polyethylene glycols that are liquid at room temperature (e.g., PEG 400 and PEG 600).
[0024] In one embodiment, the suspension further comprises one or more components selected from the group consisting of polysorbates, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropylmethylcellulose.
[0025] The suspension may include one or more surfactants. Suitable surfactants include, by way of example and without limitation, polysorbates, lauryl sulfate, acetylated monoglycerides, diacetylated monoglycerides, and poloxamers.
[0026] The suspension may include one or more isotonicity agents. Suitable isotonicity agents include, by way of example and without limitation, one or more inorganic salts, electrolytes, sodium chloride, potassium chloride, sodium phosphate, potassium phosphate, sodium, potassium sulfate, sodium and potassium bicarbonate, and alkaline earth metal inorganic salts, e.g., alkaline earth metal salts such as calcium and magnesium salts, mannitol, dextrose, glycerin, propylene glycol, and mixtures thereof.
[0027] In an embodiment particularly suitable for intraperitoneal (IP) administration, the suspension may be formulated to be hyperosmolar (hypertonic), hypoosmolar (hypotonic), or isotonic (isotonic) with respect to the fluid of the IP cavity. In some embodiments, the suspension may be isotonic with respect to the fluid in the IP cavity. In such embodiments, the osmolality of the suspension may range from about 200 to about 380, about 240 to about 340, about 280 to about 300, or about 290 mOsm / kg.
[0028] The suspension may include one or more buffering agents. Suitable buffering agents include, by way of example and without limitation, dibasic sodium phosphate, monobasic sodium phosphate, citric acid, sodium citrate, hydrochloric acid, sodium hydroxide, tris(hydroxymethyl)aminomethane, bis(2-hydroxyethyl)iminotris-(hydroxymethyl)methane, and sodium bicarbonate, as well as others known to those skilled in the art. Buffers are generally used to adjust the pH to a desired range for intraperitoneal use. Typically, a pH of about 5-9, 5-8, 6-7.4, 6.5-7.5, or 6.9-7.4 is desired.
[0029] The suspension may include one or more demulcents. Demulcents are agents that form a soothing film over mucous membranes such as the peritoneum and membranes that cover organs. Demulcents can relieve minor pain and inflammation and are sometimes referred to as mucosal protectants. Suitable demulcents, when used with another polymeric demulcent described herein, include cellulose derivatives in the range of about 0.2 to about 2.5%, such as sodium carboxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, and methylcellulose; about 0.01% gelatin; about 0.05 to about 1%, including about 0.05 to about 1%, polyols such as glycerin, polyethylene glycol 300, polyethylene glycol 400, polysorbate 80, and propylene glycol; about 0.1 to about 4% polyvinyl alcohol; about 0.1 to about 2% povidone; and from about 0.1% dextran 70.
[0030] The suspension may include one or more alkalinizing agents to adjust the pH. As used herein, the term "alkalinizing agent" is intended to mean a compound used to provide an alkaline medium. Such compounds include, by way of example and without limitation, ammonia solution, ammonium carbonate, potassium hydroxide, sodium carbonate, sodium bicarbonate, and sodium hydroxide, as well as others known to those skilled in the art.
[0031] The suspension may contain one or more acidifying agents to adjust pH. As used herein, the term "acidifying agent" is intended to mean a compound used to provide an acidic medium. Such compounds include, by way of example and without limitation, acetic acid, amino acids, citric acid, nitric acid, fumaric acid and other alphahydroxy acids, hydrochloric acid, ascorbic acid, and nitric acid, as well as others known to those skilled in the art.
[0032] The suspension may contain one or more antifoaming agents.As used herein, the term "antifoaming agent" is intended to mean a compound or compounds that prevent or reduce the amount of foam that forms on the surface of the fill composition.Suitable antifoaming agents include, by way of example and without limitation, dimethicone, simethicone (registered trademark), octoxynol, and others known to those skilled in the art.
[0033] The suspension may contain one or more viscosity modifiers that increase or decrease the viscosity of the suspension. Suitable viscosity modifiers include methylcellulose, hydroxypropylmethycellulose, mannitol and polyvinylpyrrolidone.
[0034] The suspension may include one or more osmotic agents, such as those used in peritoneal dialysis. Suitable osmotic agents include icodextrin (a glucose polymer), sodium chloride, potassium chloride, and salts also used as buffering agents.
[0035] In one embodiment, a liquid suspension of niraparib particles may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosol droplets of the liquid suspension may be any diameter suitable for use. In one embodiment, the aerosol droplets have a mass median aerodynamic diameter of about 0.5 μm to about 6 μm. In various further embodiments, the aerosol droplets have a diameter of about 0.5 μm to about 5.5 μm, about 0.5 μm to about 5 μm, about 0.5 μm to about 4.5 μm, about 0.5 μm to about 4 μm, about 0.5 μm to about 3.5 μm, about 0.5 μm to about 3 μm, about 0.5 μm to about 2.5 μm, about 0.5 μm to about 2 μm, about 1 μm to about 5.5 μm, about 1 μm to about 5 μm, about 1 μm to about 4.5 μm, about 1 μm to about 4 μm, about 1 μm to about 3.5 μm, about 1 μm to about 3 μm, about 1 μm to about 2.5 μm. , having a diameter of about 1 μm to about 2 μm, a diameter of about 1.5 μm to about 5.5 μm, a diameter of about 1.5 μm to about 5 μm, a diameter of about 1.5 μm to about 4.5 μm, a diameter of about 1.5 μm to about 4 μm, a diameter of about 1.5 μm to about 3.5 μm, a diameter of about 1.5 μm to about 3 μm, a diameter of about 1.5 μm to about 2.5 μm, a diameter of about 1.5 μm to about 2 μm, a diameter of about 2 μm to about 5.5 μm, a diameter of about 2 μm to about 5 μm, a diameter of about 2 μm to about 4.5 μm, a diameter of about 2 μm to about 4 μm, a diameter of about 2 μm to about 3.5 μm, a diameter of about 2 μm to about 3 μm, and a diameter of about 2 μm to about 2.5 μm. A suitable instrument for measuring the median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of aerosol droplets is a seven-stage aerosol sampler, such as a Mercer-style cascade impactor. Liquid suspensions of niraparib particles delivered by the s may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating aerosols may be used, including, but not limited to, metered dose inhalers (MDIs), pressurized metered dose inhalers (pMDIs), nebulizers, and soft mist inhalers.
[0036] In one embodiment, a dry powder composition of niraparib particles may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosolized dry powder composition may be any diameter suitable for use. The dry powder composition is formulated as a dry powder. The dry powder composition may comprise niraparib particles alone, without a carrier, or may comprise niraparib particles and a pharma- ceutically acceptable dry powder carrier, including one or more dry powder excipients. In one embodiment, the aerosolized dry powder composition has an MMAD of about 0.5 μm to about 6 μm in diameter. In various further embodiments, the aerosolized dry powder composition has a diameter of about 0.5 μm to about 5.5 μm, about 0.5 μm to about 5 μm, about 0.5 μm to about 4.5 μm, about 0.5 μm to about 4 μm, about 0.5 μm to about 3.5 μm, about 0.5 μm to about 3 μm, about 0.5 μm to about 2.5 μm, about 0.5 μm to about 2 μm, about 1 μm to about 5.5 μm, about 1 μm to about 5 μm, about 1 μm to about 4.5 μm, about 1 μm to about 4 μm, about 1 μm to about 3.5 μm, about 1 μm to about 3 μm, about 1 μm to about 2. 5 μm, about 1 μm to about 2 μm in diameter, about 1.5 μm to about 5.5 μm in diameter, about 1.5 μm to about 5 μm in diameter, about 1.5 μm to about 4.5 μm in diameter, about 1.5 μm to about 4 μm in diameter, about 1.5 μm to about 3.5 μm in diameter, about 1.5 μm to about 3 μm in diameter, about 1.5 μm to about 2.5 μm in diameter, about 1.5 μm to about 2 μm in diameter, about 2 μm to about 5.5 μm in diameter, about 2 μm to about 5 μm in diameter, about 2 μm to about 4.5 μm in diameter, about 2 μm to about 4 μm in diameter, about 2 μm to about 3.5 μm in diameter, about 2 μm to about 3 μm in diameter, and about 2 μm to about 2.5 μm in diameter. Suitable instruments for measuring the median aerodynamic diameter (MMAD) and geometric standard deviation (GSD) of dry powder compositions are a seven-stage aerosol sampler such as a Mercer-style cascade impactor or an aerodynamic particle sizer spectrometer such as the APS™ Model 3321 spectrometer available from TSI Inc. Dry powder compositions delivered by aerosol may be deposited in the respiratory tract by gravitational settling, inertial impaction, and / or diffusion.Any device suitable for generating an aerosol of the dry powder composition may be used, including but not limited to a dry powder inhaler (DPI). Examples of excipients suitable for dry powder inhalable compositions include, but are not limited to, lactose of a grade suitable for inhalation. In one embodiment, the composition is a dry powder composition suitable for pulmonary delivery by inhalation via aerosolization.
[0037] As used herein, a "pharmaceutically acceptable salt" of niraparib is, within the scope of sound medical judgment, suitable for use in contact with patient tissues without undue toxicity, irritation, allergic reaction, etc., commensurate with a reasonable benefit / risk ratio, and effective for their intended use, including, where possible, zwitterionic forms of niraparib. The term "salt" refers to relatively non-toxic inorganic and organic acid addition salts of niraparib. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, malate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthylate, mesylate, glucoheptonate, lactobionate, laurylsulfonate, and the like. These may include cations based on alkali and alkaline earth metals, such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. (See, e.g., Berge SM et al., "Pharmaceutical Salts", J. Pharm. Sci., 1977;66:1-19, incorporated herein by reference.) In one embodiment, a pharma- ceutically acceptable salt of niraparib includes niraparib tosylate monohydrate, which is 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole 7-carboxamide 4-methylbenzenesulfonic acid ester hydrate (1:1:1).
[0038] In one embodiment, the composition comprises a dosage form of niraparib in a suspension (i.e.: together with a pharma- ceutically acceptable carrier and any other ingredients) at a dosage deemed appropriate by the attending physician for the intended use. Any suitable dosage form may be used, and in various non-limiting embodiments, the dosage form is sufficient to provide from about 0.01 mg / kg to about 50 mg / kg of body weight per day. In various further embodiments, the dosage form is sufficient to provide about 0.01 mg / kg to about 45 mg / kg, about 0.01 mg / kg to about 40 mg / kg, about 0.01 mg / kg to about 35 mg / kg, about 0.01 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 25 mg / kg, about 0.01 mg / kg to about 20 mg / kg, about 0.01 mg / kg to about 15 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 5 mg / kg, or about 0.01 mg / kg to about 1 mg / kg of body weight per day. The suspension may be administered as or diluted with a diluent, such as saline for injection, optionally including a buffer and one or more other excipients, prior to administration. For example, the volume ratio of the suspension to the diluent may be within the range of 1:1 to 1:100 (v / v) or other suitable ratio.
[0039] In another aspect, the present disclosure provides a method for treating tumors, comprising administering to a subject having a tumor an effective amount of a composition or suspension of any embodiment or combination of embodiments of the present disclosure to treat the tumor. The increased specific surface area of the niraparib particles of the present disclosure results in a significant increase in the dissolution rate of the particles compared to currently available niraparib. This provides a significant improvement for the use of the particles of the present disclosure, for example, in the treatment of tumors. Furthermore, in some embodiments, the method of the present disclosure can reduce the dosing frequency and side effects of niraparib. As a non-limiting example, since the systemic concentration is greatly reduced, the niraparib dose administered by direct injection into tumors is expected to be substantially lower, the dosing frequency is lower compared to oral dosing, and there are fewer side effects.
[0040] As used herein, "tumor" includes benign tumors, precancerous tumors, malignant tumors that have not metastasized, and malignant tumors that have metastasized. The methods of the present disclosure can be used to treat tumors that are susceptible to niraparib treatment, including, but not limited to, carcinomas, breast tumors, pancreatic tumors, prostate tumors, fallopian tube tumors, peritoneal tumors, bladder tumors, lung tumors, ovarian tumors, gastrointestinal tumors, testicular tumors, cervical tumors, head and neck tumors, esophageal tumors, mesothelioma, brain tumors, neuroblastoma, or renal cell tumors. In certain embodiments, the tumor is a fallopian tube tumor, a peritoneal tumor, or an ovarian tumor; in other embodiments, the tumor is an advanced epithelial ovarian cancer, a fallopian tube tumor, or a primary peritoneal tumor.
[0041] In another embodiment, the method further comprises administering to the subject an additional therapeutic agent, including but not limited to, an anthracycline, an antimetabolite, an alkylating agent (including but not limited to cisplatin), an alkaloid, a taxane (including but not limited to paclitaxel, docetaxel, cabazitaxel, and combinations thereof), and / or a topoisomerase inhibitor.
[0042] The subject may be any suitable subject having a tumor, including, but not limited to, a human, a primate, a dog, a cat, a horse, a cow, etc. In one embodiment, the subject is a human subject. In some embodiments, a subject, such as a human subject, has (i) progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to initial platinum-based chemotherapy, (ii) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, or (iii) has been treated with three or more prior chemotherapy regimens, and the cancer is: harmful or suspected harmful BRCA mutations, or Genomic instability Patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that has responded to the last platinum-based chemotherapy regimen more than 6 months prior to the initial platinum-based chemotherapy regimen were associated with homologous recombination repair deficiency (HRD)-positive status as defined by either
[0043] As used herein, "treat" or "treating" means achieving one or more of the following: (a) reducing the severity of the disorder; (b) limiting or preventing the onset of symptoms characteristic of the disorder being treated; (c) inhibiting or exacerbating symptoms characteristic of the disorder being treated; (d) limiting or preventing the recurrence of the disorder in a patient who already has the disorder; and (e) limiting or preventing the recurrence of symptoms in a patient who is previously symptomatic of the disorder.
[0044] The amount effective for these uses will depend on factors including, but not limited to, the nature of niraparib (such as specific activity), the route of administration, the stage and severity of the disorder, the weight and general health of the subject, and the judgment of the prescribing physician. It will be understood that the amount of the suspension composition of the present disclosure actually administered will be determined by the physician in light of the relevant circumstances described above. In one non-limiting embodiment, the effective amount is an amount that provides 0.01 mg / kg to about 50 mg / kg of body weight per day.
[0045] In a further embodiment, the composition comprises a liquid suspension further comprising a pharmacy acceptable liquid carrier. The suspension of the present disclosure comprises niraparib particles and a liquid carrier. All embodiments of the suspension and liquid carrier disclosed herein may be used in the therapeutic methods of the present disclosure.
[0046] In one embodiment, a liquid suspension of niraparib particles for therapeutic use may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosol droplets of the liquid suspension may be any suitable diameter for use, and all embodiments disclosed herein may be used in the therapeutic methods of the present disclosure. The liquid suspension of niraparib particles delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating aerosols may be used, including, but not limited to, metered dose inhalers (MDIs), pressurized metered dose inhalers (pMDIs), nebulizers, and soft mist inhalers.
[0047] In one embodiment, the dry powder composition of niraparib particles for therapeutic use may be aerosolized for pulmonary administration by inhalation, and the mass median aerodynamic diameter (MMAD) of the aerosolized dry powder composition may be any suitable diameter for use, and all embodiments disclosed herein may be used in the therapeutic methods of the present disclosure. The dry powder composition delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating an aerosol of the dry powder composition may be used in the therapeutic methods of the present disclosure, including but not limited to a dry powder inhaler (DPI). Examples of excipients suitable for dry powder inhalable compositions include, but are not limited to, lactose of a grade suitable for inhalation. In one embodiment, the composition is a dry powder composition administered by inhalation via aerosolization.
[0048] In one embodiment, the composition comprises a dosage form of niraparib in a suspension (i.e.: together with a pharma- ceutically acceptable carrier and any other ingredients) at a dosage deemed appropriate by the attending physician for the intended use. Any suitable dosage form may be used, and in various non-limiting embodiments, the dosage form is sufficient to provide from about 0.01 mg / kg to about 50 mg / kg of body weight per day. In various further embodiments, the dosage form is sufficient to provide about 0.01 mg / kg to about 45 mg / kg, about 0.01 mg / kg to about 40 mg / kg, about 0.01 mg / kg to about 35 mg / kg, about 0.01 mg / kg to about 30 mg / kg, about 0.01 mg / kg to about 25 mg / kg, about 0.01 mg / kg to about 20 mg / kg, about 0.01 mg / kg to about 15 mg / kg, about 0.01 mg / kg to about 10 mg / kg, about 0.01 mg / kg to about 5 mg / kg, or about 0.01 mg / kg to about 1 mg / kg of body weight per day. A suspension that is or can be diluted with a diluent may be administered.
[0049] The compositions may be administered via any appropriate route, including but not limited to oral, pulmonary, intraperitoneal, intratumoral, peritumoral, subcutaneous injection, intramuscular injection, administration into the mammary fat pad, or any other form of injection, as deemed most suitable by the attending medical practitioner in light of all factors relevant to the particular subject.
[0050] In one embodiment, pulmonary administration includes inhalation of a single dose of niraparib particles, such as by nasal inhalation, oral inhalation, or both. Niraparib particles may be administered in two or more separate administrations (doses). In this embodiment, the particles may be formulated as an aerosol (i.e.: liquid droplets of a stable dispersion or suspension of particles in a gas medium). Niraparib particles delivered by aerosol may be deposited in the airways by gravitational settling, inertial impaction, and / or diffusion. Any device suitable for generating aerosols may be used, including, but not limited to, metered dose inhalers (MDIs), pressurized metered dose inhalers (pMDIs), nebulizers, and soft mist inhalers.
[0051] In a particular embodiment, the method comprises inhalation of aerosolized niraparib particles via nebulization. Nebulizers typically use compressed air or ultrasonic power to generate inhalable aerosol droplets of particles or a suspension thereof. In this embodiment, nebulization results in pulmonary delivery of aerosol droplets of niraparib particles or a suspension thereof to the subject.
[0052] In another embodiment, the method comprises inhalation of aerosolized niraparib particles via a pMDI, where the particles or a suspension thereof are suspended in at least one liquefied gas containing a suitable propellant system (including but not limited to hydrofluoroalkanes (HFAs)) in a pressurized container sealed with a metering valve. Actuation of the valve results in delivery of a metered dose of an aerosol spray of niraparib particles or a suspension thereof.
[0053] In another embodiment, the method comprises inhaling a dry powder composition of niraparib via a DPI, the dry powder composition comprising niraparib particles alone without a carrier. In yet another embodiment, the method comprises inhaling a dry powder composition of niraparib via a DPI, the dry powder composition comprising niraparib particles and may comprise a pharma- ceutically acceptable dry powder carrier comprising one or more dry powder excipients. Examples of suitable dry powder excipients for dry powder inhalable compositions include, but are not limited to, lactose of a grade suitable for inhalation.
[0054] A dosing period is the period during which a dose of niraparib particles in a composition or suspension is administered. A dosing period can be a single period during which the entire dose is administered, or it can be divided into two or more periods during which a portion of the dose is administered.
[0055] The post-dosing period is the period that begins after the completion of the previous dosing period and ends after the initiation of the subsequent dosing period. The duration of the post-dosing period can be changed depending on the subject's clinical response to niraparib. No suspension is administered during the post-dosing period. The post-dosing period can last for at least 7 days, at least 14 days, at least 21 days, at least 28 days, at least 35 days, at least 60 days, or at least 90 days or more. The post-dosing period can be kept constant for a subject, or two or more different post-dosing periods can be used for a subject.
[0056] A dosing cycle includes a dosing period and a post-dosing period.Therefore, the duration of a dosing cycle is the sum of the dosing period and the post-dosing period.The dosing cycle can be kept constant for a subject, or two or more different dosing cycles can be used for a subject.
[0057] In one embodiment, administration is performed more than once, with each administration separated by at least 21 days.
[0058] In another aspect, the present disclosure provides a method for making niraparib particles, comprising: (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), or a combination thereof, and at least one solute, including niraparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a vessel defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into a pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2 mm to 20 mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20 μm to 125 μm; (c) contacting the atomized droplets with a compressed fluid to cause removal of solvent from the atomized droplets to produce niraparib particles comprising at least 95% niraparib or a pharma- ceutically acceptable salt thereof, wherein the niraparib particles have a diameter of at least 2.5 mm; 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method is provided wherein steps (a), (b) and (c) are carried out under the supercritical temperature and pressure of the compressed fluid.
[0059] The method utilizes a sonic energy source located directly in the exhaust stream of solutes dissolved in a solvent. Any suitable source of sonic energy compatible with the methods of the present disclosure may be used, including but not limited to a sonic horn, sonic probe, or sonic plate. In various embodiments, the nozzle orifice is located about 2 mm to about 20 mm, about 2 mm to about 18 mm, about 2 mm to about 16 mm, about 2 mm to about 14 mm, about 2 mm to about 12 mm, about 2 mm to about 10 mm, about 2 mm to about 8 mm, about 2 mm to about 6 mm, about 2 mm to about 4 mm, about 4 mm to about 20 mm, about 4 mm to about 18 mm, about 4 mm to about 16 mm, about 4 mm to about 14 mm, about 4 mm to about 12 mm, about 4 mm to about 10 mm, about 4 mm to about 8 mm, about 4 mm to about 6 mm, about 6 mm to about 20 mm, about 6 mm to about 18 mm, about 6 mm to about 16 mm, about 6 mm to about 14 mm, about 6 mm to about 12 mm, about 6 mm to about 6 ... m to about 10 mm, about 6 mm to about 8 mm, about 8 mm to about 20 mm, about 8 mm to about 18 mm, about 8 mm to about 16 mm, about 8 mm to about 14 mm, about 8 mm to about 12 mm, about 8 mm to about 10 mm, about 10 mm to about 20 mm, about 10 mm to about 18 mm, about 10 mm to about 16 mm, about 10 mm to about 14 mm, about 10 mm to about 12 mm, about 12 mm to about 20 mm, about 12 mm to about 18 mm, about 12 mm to about 16 mm, about 12 mm to about 14 mm, about 14 mm to about 20 mm, about 14 mm to about 18 mm, about 14 mm to about 16 mm, about 16 mm to about 20 mm, about 16 mm to about 18 mm, and about 18 mm to about 20 mm. In a further embodiment, the nozzle assembly of any embodiment of WO 2016 / 197091 may be used.
[0060] Any suitable source of sonic energy compatible with the methods of the present disclosure may be used, including, but not limited to, a sonic horn, a sonic probe, or a sonic plate. In various further embodiments, the sonic energy source produces sonic energy having an amplitude of about 10% to about 100% of the total power that can be generated using the sonic energy source. In light of the teachings herein, one of skill in the art can determine an appropriate sonic energy source having a particular total power output to be used. In one embodiment, the sonic energy source has a total power output of about 500 to about 900 watts; in various further embodiments, about 600 to about 800 watts, about 650 to 750 watts, or about 700 watts.
[0061] In various further embodiments, the sonic energy source is about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 90% to about 100%, about 100% of the total power that can be generated using the sonic energy source. % to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 80% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, about 60% to about 80%, about 70% to About 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, about 50% to about 70%, about 60% to about 70%, about 10% to about 60%, about 20% to about 60%, about 30% to about 60%, about 40% to about 60%, about 50% to about 60%, about 10% to about 50%, about 20% to about 50%, about 30% to about The sonic energy source may generate sonic energy having an output of about 50%, about 40% to about 50%, about 10% to about 40%, about 20% to about 40%, about 30% to about 40%, about 10% to about 30%, about 20% to about 30%, about 10% to about 20%, or about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or about 100%. In light of the teachings herein, one of ordinary skill in the art can determine the appropriate frequency to be utilized in the sonic energy source. In one embodiment, a frequency of about 18 to about 22 kHz is utilized in the sonic energy source. In various other embodiments, a frequency of about 19 to about 21 kHz, about 19.5 to about 20.5, or about 20 kHz is utilized in the sonic energy source.
[0062] In various further embodiments, the nozzle orifice may be from about 20 μm to about 125 μm, from about 20 μm to about 115 μm, from about 20 μm to about 100 μm, from about 20 μm to about 90 μm, from about 20 μm to about 80 μm, from about 20 μm to about 70 μm, from about 20 μm to about 60 μm, from about 20 μm to about 50 μm, from about 20 μm to about 40 μm, from about 20 μm to about 30 μm, from about 30 μm to about 125 μm, from about 30 μm to about 115 μm, from about 30 μm to about 100 μm, from about 30 μm to about 9 0μm, about 30μm to about 80μm, about 30μm to about 70μm, about 30μm to about 60μm, about 30μm to about 50μm, about 30μm to about 40μm, about 40μm to about 125μm, about 40μm to about 115μm, about 40μm to about 1 00μm, about 40μm to about 90μm, about 40μm to about 80μm, about 40μm to about 70μm, about 40μm to about 60μm, about 40μm to about 50μm, about 50μm to about 125μm, about 50μm to about 115μm, about 50μm to about 1 00μm, about 50μm to about 90μm, about 50μm to about 80μm, about 50μm to about 70μm, about 50μm to about 60μm, about 60μm to about 125μm, about 60μm to about 115μm, about 60μm to about 100μm, about 60μm Approximately 90μm, approximately 60μm to approximately 80μm, approximately 60μm to approximately 70μm, approximately 70μm to approximately 125μm, approximately 70μm to approximately 115μm, approximately 70μm to approximately 100μm, approximately 70μm to approximately 90μm, approximately 70μm to approximately 80μm, approximately 80μm The nozzle has a diameter of about 125 μm, about 80 μm to about 115 μm, about 80 μm to about 100 μm, about 80 μm to about 90 μm, about 90 μm to about 125 μm, about 90 μm to about 115 μm, about 90 μm to about 100 μm, about 100 μm to about 125 μm, about 100 μm to about 115 μm, about 115 μm to about 125 μm, about 20 μm, 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 115 μm, or about 120 μm. The nozzle is inert to both the solvent and compressed fluid used in the method.
[0063] The solvent includes ethanol, methanol, hexafluoroisopropanol (HFIP), or a combination thereof. The solvent should comprise at least about 80%, 85%, or 90% by weight of the total solution.
[0064] The compressed fluid can form a supercritical fluid under the conditions used, and the solutes forming the particles are poorly soluble or insoluble in the compressed fluid. As known to those skilled in the art, a supercritical fluid is any substance at a temperature and pressure above its critical point, and no distinct liquid or gas phases exist. Steps (a), (b), and (c) of the method of the present disclosure are carried out under the supercritical temperature and pressure of the compressed fluid, so that the compressed fluid exists as a supercritical fluid during these processing steps.
[0065] The compressed fluid can function as a solvent and can be used to remove unwanted components within the particles. Any suitable compressed fluid may be used in the disclosed method; such representative compressed fluids are disclosed in U.S. Pat. Nos. 5,833,891 and 5,874,029. In one non-limiting embodiment, suitable supercritical fluid forming compressed fluids and / or anti-solvents can include carbon dioxide, ethane, propane, butane, isobutane, nitrous oxide, xenon, sulfur hexafluoride, and trifluoromethane. The anti-solvents listed in step (d) to cause further solvent removal are compressed fluids as defined above and may be the same compressed fluids used in steps (a-c) or may be different. In one embodiment, the anti-solvent used in step (d) is the same compressed fluid used in steps (a-c). In a preferred embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide.
[0066] In all cases, the compressed fluid and anti-solvent should be substantially miscible with the solvent, but niraparib should be substantially insoluble in the compressed fluid, i.e., niraparib should be soluble at about 5% by weight or less in the compressed fluid or anti-solvent at the selected solvent / compressed fluid contact conditions, and preferably essentially completely insoluble.
[0067] The supercritical state used in the method of the present disclosure is typically within a range of 1 to about 1.4 times, or 1 to about 1.2 times, the critical temperature of the supercritical fluid, and within a range of 1 to about 7 times, or 1 to about 2 times, the supercritical pressure of the compressed fluid.
[0068] It is well within the level of one of ordinary skill in the art to determine the critical temperature and pressure for a given compressed fluid or anti-solvent. In one embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide, the critical temperature is at least 31.1° C. and not more than about 60° C., and the critical pressure is at least 1071 psi and not more than about 1800 psi. In another embodiment, the compressed fluid and anti-solvent are both supercritical carbon dioxide, the critical temperature is at least 35° C. and not more than about 55° C., and the critical pressure is at least 1070 psi and not more than about 1500 psi. It will be understood by one of ordinary skill in the art that the specific critical temperatures and pressures may be different at various steps during processing.
[0069] Any suitable pressurizable chamber may be used, including but not limited to those disclosed in WO 2016 / 197091 or US Patent Nos. 5,833,891 and 5,874,029. Similarly, the step of contacting the atomized droplets with a compressed fluid to cause removal of the solvent from the droplets; and the step of contacting the droplets with an anti-solvent to cause further removal of the solvent from the droplets to produce particles of the compound may be carried out under any suitable conditions, including but not limited to those disclosed in US Patent Nos. 5,833,891 and 5,874,029.
[0070] The flow rate can be adjusted to be as high as possible to optimize the output, but below the pressure limits of the device including the nozzle orifice. In one embodiment, the flow rate of the solution through the nozzle ranges from about 0.5 mL / min to about 30 mL / min. In various further embodiments, the flow rate is about 0.5 mL / min to about 25 mL / min, 0.5 mL / min to about 20 mL / min, 0.5 mL / min to about 15 mL / min, 0.5 mL / min to about 10 mL / min, 0.5 mL / min to about 4 mL / min, about 1 mL / min to about 30 mL / min, about 1 mL / min to about 25 mL / min, about 1 mL / min to about 20 mL / min, 1 mL / min to about 15 mL / min, about 1 mL / min to about 10 mL / min, about 2 mL / min to about 30 mL / min, about 2 mL / min to about 25 mL / min, about 2 mL / min to about 20 mL / min, about 2 mL / min to about 15 mL / min, or about 2 mL / min to about 10 mL / min. The solution of the drug affected by the flow rate can be any suitable concentration, such as about 1 mg / ml to about 80 mg / ml.
[0071] In one embodiment, the method further includes receiving the plurality of particles through an outlet of the pressurizable chamber; and collecting the plurality of particles in a collection device such as disclosed in WO 2016 / 197091.
[0072] In another aspect, the present disclosure provides niraparib particles prepared by a method of any embodiment or combination of embodiments of the present disclosure.
[0073] Working Example
[0074] [Table 1]
[0075] Material Testing Particle Size Distribution (PSD) by Laser Diffraction Scanning Electron Microscope (SEM) Imaging Specific surface area (SSA) measurement by BET yield measurement Crystalline / amorphous phase determination by powder X-ray diffraction (PXRD) Modified USP <616> Bulk density analysis of powders by method I. Dissolution using USP Apparatus 2
[0076] the study 1. Solvent solubility study of Niraparib in various solvents. 2. Demonstration of precipitation of Niraparib from three solvent systems and subsequent analysis of the corresponding materials for / by PSD, SEM, PXRD, SSA, bulk density and dissolution.
[0077] The solubility of Niraparib was tested in the following solvent mixtures: Ethanol only, Methanol only, and HFIP only.
[0078] Four small-scale precipitation experiments were performed with niraparib on an RC612B precipitation unit. Precipitates from the experiments were analyzed by laser diffraction to determine the PSD, by SEM to determine the shape / properties supporting the PSD data, by BET yield measurements to determine the SSA, by PXRD to determine the crystalline / amorphous phase of the material, and by bulk density analysis to identify additional physical characteristics of the precipitate. Dissolution studies were performed to compare the dissolution rate of precipitated niraparib to the unprocessed drug substance.
[0079] Experimental procedure Receiving materials Niraparib was obtained from BOC Sciences and stored in a temperature-humidity monitored cabinet.
[0080] Solvent Selection Solubility in organic solvents greater than about 8 mg / mL at room temperature was deemed sufficient for further study, with higher solvent solubility resulting in shorter production times. Solubility was determined by visual observation and tested according to standard operating procedures.
[0081] Precipitation Following standard operating procedures, four small precipitates of niraparib were generated on an RC612B SCP unit.
[0082] In one particular representative method, a 20 mg / mL solution of niraparib was prepared in ethanol. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated niraparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 37.8°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The ethanol solution containing niraparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 12.5 minutes. The precipitated niraparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the niraparib particles was opened and the resulting product was collected from the filter.
[0083] In one particular representative method, a 67 mg / mL solution of niraparib was prepared in methanol. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated niraparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility and brought to approximately 1200 psi at approximately 37.5°C and a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The methanol solution containing niraparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 4 minutes. The precipitated niraparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the niraparib particles was opened and the resulting product was collected from the filter.
[0084] In one particular representative method, a 100 mg / mL solution of niraparib was prepared in HFIP. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated niraparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 37.5°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The HFIP solution containing niraparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 2.5 minutes. The precipitated niraparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the niraparib particles was opened and the resulting product was collected from the filter.
[0085] In one particular representative method, a 50 mg / mL solution of niraparib was prepared in methanol. The nozzle and sonic probe were positioned approximately 9 mm apart in a pressurizable chamber. A stainless steel membrane filter with a nominal rating of approximately 20 nm was attached to the pressurizable chamber to collect precipitated niraparib particles. Supercritical carbon dioxide was placed in the pressurizable chamber of the manufacturing facility at approximately 38.0°C and approximately 1200 psi with a flow rate of 4-12 kg / hr. The sonic probe was adjusted to an amplitude of 60% of maximum output with a frequency of 20 kHz. The methanol solution containing niraparib was pumped through the nozzle at a flow rate of 2 mL / min for approximately 100 minutes. The precipitated niraparib particles were then collected from the supercritical carbon dioxide while the mixture was pumped through a stainless steel mesh filter. The filter containing the niraparib particles was opened and the resulting product was collected from the filter.
[0086] Analytical Testing Following precipitation experiments of niraparib, the materials were analyzed for / by PSD, SEM, PXRD, SSA, bulk density and dissolution, where applicable.
[0087] Results and Discussion Solvent Selection All results are shown in Table 1.
[0088] Precipitation The first precipitation experiment (SC1) was performed with ethanol, the second with methanol (SC2). The third experiment (SC3) was performed with HFIP. The precipitation experiment grid is shown in Table 1.
[0089] [Table 2]
[0090] Particle size distribution Particle size analysis was performed on a Malvern Mastersizer™ 3000 using a Hydro MV™ dispersion unit. Niraparib samples were analyzed using an unvalidated generic PSD / dispersant method. The sample preparation procedure performed was as follows: weigh 10-20 mg of niraparib into a 30 mL vial and add 20 mL of ethyl acetate. Disperse the sample by vortexing the suspension for 1 min in an ultrasonic bath and then sonicating. The sample suspension is then transferred to a Malvern Hydro MV™ dispersion unit to obtain a decay rate of 5-15%.
[0091] PSD results were obtained ranging from a Dv10 of 0.601μ to a Dv90 of 12.9μ. The Dv50 results for the four runs ranged from 2.32μ to 5.74μ, significantly smaller than that observed for the raw material. The particle size distribution can be seen in Table 1.
[0092] Scanning electron microscopy Scanning electron microscopy was performed on a Joel NeoScope™ SEM. Overall, the imaging supports the particle size distribution results with varying distribution and various particle shapes / properties. Representative SEM micrographs are presented in Figures 1-5.
[0093] Powder X-ray diffraction Powder X-ray diffraction analysis was performed on a Siemens D5000 X-ray diffractometer. PXRD was scanned from 5 to 35 2θ degrees at a speed of 0.02 2θ degrees / sec and 1 sec per step. An overlay of the diffraction patterns can be seen in Figure 6.
[0094] specific surface area Surface area analysis was performed on a Quantachrome NOVAtouch™ LX2 BET Sorptometer. The surface area results can be found in Table 1.
[0095] Solubility Test The solubility was measured by using the shake flask method. The drug was added in duplicate to each solution prepared in excess. The vials were placed on a mechanical shaker at 20-25°C for 24 hours. After shaking, the solutions were removed, filtered through 0.45 μm PTFE syringe filters, and analyzed by UV / Visible spectrophotometry. The results are shown in Table 2 and suggest that niraparib exhibited concentration-dependent solubility.
[0096] [Table 3]
[0097] Dissolution Test The medium selected for dissolution testing was 900 mL of 10% methanol-water with a paddle speed of 50 rpm. To meet the sink condition, 20 mg of drug was added directly to the vessel. The two vessels were filled with 11.96 m 2 The two containers contained treated SC4 material with a specific surface area measurement of 0.70 m 2 The samples contained untreated material with specific surface area measurements of 1000 μg / g. Time points were taken at 5, 10, 15, and 30 min. At each time point, a 5 mL aliquot was removed and immediately filtered through a 0.45 μm PTFE syringe filter, discarding the first 1 mL of filtrate. The solution was then analyzed by UV / Visible spectrophotometry at a wavelength of 240 nm. The elution profile is presented in Figure 7 and shows good differentiation between samples with various specific surface areas.
[0098] conclusion Niraparib was successfully precipitated from all solvent systems tested, with ethanol and methanol showing the most promising results. The resulting niraparib particles showed significantly increased specific surface area and significantly improved dissolution properties.
Claims
1. 1. A composition comprising particles comprising at least 95% by weight of niraparib, or a pharma- ceutically acceptable salt thereof, wherein the particles have a diameter of at least 5 mm. 2 / g, 6m 2 / g, 7m 2 / g, 8m 2 / g, 9m 2 / g, 10m 2 / g, 11m 2 / g, 12m 2 / g, 13m 2 / g, 14m 2 / g, 15m 2 / g, 16m 2 / g, 17m 2 / g, 18m 2 / g, 19m 2 / g, 20m 2 / g, 21m 2 / g, 22m 2 / g, 23m 2 / g, or 24m 2 / g specific surface area (SSA).
2. The particles are at least 10 m 2 The composition of claim 1 having an SSA of 0.1 to 0.5 g.
3. The particles are at least 15 m 2 The composition of claim 1 having an SSA of 0.1 to 0.5 g.
4. Preface particle が, 5m 2 / g~about 50m 2 / g, about 6m 2 / g~about 50m 2 / g, about 7m 2 / g~about 50m 2 / g, about 8m 2 / g~about 50m 2 / g, about 9m 2 / g~about 50m 2 / g, about 10m 2 / g~about 50m 2 / g, about 11m 2 / g~about 50m 2 / g, about 12m 2 / g~about 50m 2 / g, about 13m 2 / g~about 50m 2 / g, about 14m 2 / g~about 50m 2 / g, about 15m 2 / g~about 50m 2 / g, about 16m 2 / g~about 50m 2 / g, about 17m 2 / g~about 50m 2 / g, about 18m 2 / g~about 50m 2 / g, about 19m 2 / g~about 50m 2 / g, about 20m 2 / g~about 50m 2 / g, about 21m 2 / g~about 50m 2 / g, about 22m 2 / g~about 50m 2 / g, about 23m 2 / g~about 50m 2 / g, about 24m 2 / g~about 50m 2 / g, 5m 2 / g~about 45m 2 / g, about 6m 2 / g~about 45m 2 / g, about 7m 2 / g~about 45m 2 / g, about 8m 2 / g~about 45m 2 / g, about 9m 2 / g~about 45m 2 / g, about 10m 2 / g~about 45m 2 / g, about 11m 2 / g~about 45m 2 / g, about 12m 2 / g~about 45m 2 / g, about 13m 2 / g~about 45m 2 / g, about 14m 2 / g~about 45m 2 / g, about 15m 2 / g~about 45m 2 / g, about 16m 2 / g~about 45m 2 / g, about 17m 2 / g~about 45m 2 / g, about 18m 2 / g~about 45m 2 / g, about 19m 2 / g~about 45m 2 / g, about 20m 2 / g~about 45m 2 / g, about 21m 2 / g~about 45m 2 / g, about 22m 2 / g~about 45m 2 / g, about 23m 2 / g~about 45m 2 / g, about 24m 2 / g~about 45m 2 / g, 5m 2 / g~about 40m 2 / g, about 6m 2 / g~about 40m 2 / g, about 7m 2 / g~about 40m 2 / g, about 8m 2 / g~about 40m 2 / g, about 9m 2 / g~about 40m 2 / g, about 10m 2 / g~about 40m 2 / g, about 11m 2 / g~about 40m 2 / g, about 12m 2 / g~about 40m 2 / g, about 13m 2 / g~about 40m 2 / g, about 14m 2 / g~about 40m 2 / g, about 15m 2 / g~about 40m 2 / g, about 16m 2 / g~about 40m 2 / g, about 17m 2 / g~about 40m 2 / g, about 18m 2 / g~about 40m 2 / g, about 19m 2 / g~about 40m 2 / g, about 20m 2 / g~about 40m 2 / g, about 21m 2 / g~about 40m 2 / g, about 22m 2 / g~about 40m 2 / g, about 23m 2 / g~about 40m 2 / g, about 24m 2 / g~about 40m 2 / g, 5m 2 / g~about 35m 2 / g, about 6m 2 / g~about 35m 2 / g, about 7m 2 / g~about 35m 2 / g, about 8m 2 / g~about 35m 2 / g, about 9m 2 / g~about 35m 2 / g, about 10m 2 / g~about 35m 2 / g, about 11m 2 / g~about 35m 2 / g, about 12m 2 / g~about 35m 2 / g, about 13m 2 / g~about 35m 2 / g, about 14m 2 / g~about 35m 2 / g, about 15m 2 / g~about 35m 2 / g, about 16m 2 / g~about 35m 2 / g, about 17m 2 / g~about 35m 2 / g, about 18m 2 / g~about 35m 2 / g, about 19m 2 / g~about 35m 2 / g, about 20m 2 / g~about 35m 2 / g, about 21m 2 / g~about 35m 2 / g, about 22m 2 / g~about 35m 2 / g, about 23m 2 / g~about 35m 2 / g, about 24m 2 / g~about 35m 2 / g, 5m 2 / g~about 30m 2 / g, about 6m 2 / g~about 30m 2 / g, about 7m 2 / g~about 30m 2 / g, about 8m 2 / g~about 30m 2 / g, about 9m 2 / g~about 30m 2 / g, about 10m 2 / g~about 30m 2 / g, about 11m 2 / g~about 30m 2 / g, about 12m 2 / g~about 30m 2 / g, about 13m 2 / g~about 30m 2 / g, about 14m 2 / g~about 30m 2 / g, about 15m 2 / g~about 30m 2 / g, about 16m 2 / g~about 30m 2 / g, about 17m 2 / g~about 30m 2 / g, about 18m 2 / g~about 30m 2 / g, about 19m 2 / g~about 30m 2 / g, about 20m 2 / g~about 30m 2 / g, about 21m 2 / g~about 30m 2 / g, about 22m 2 / g~about 30m 2 / g, about 23m 2 / g~about 30m 2 / g、またはabout 24m 2 / g~about 30m 2 The composition of claim 1 having an SSA of 0.1 to 0.2 g / g.
5. 5. The composition of any one of claims 1 to 4, wherein the particles have an average particle size by volume distribution (Dv50) of from about 1.0 micron to about 10.0 microns in diameter, or from about 1 micron to about 6 microns in diameter, or from about 2 microns to about 6 microns in diameter.
6. The particles have a density of about 0.020 g / cm 3 ~Approx. 0.500g / cm 3 6. The composition of claim 1 having an average bulk density (not tapped density) of
7. The particles have a density of about 0.020 g / cm 3 ~Approx. 0.475g / cm 3 , about 0.020g / cm 3 ~Approx. 0.450g / cm 3 , about 0.020g / cm 3 ~Approx. 0.425g / cm 3 , about 0.020g / cm 3 ~Approx. 0.400g / cm 3 , about 0.020g / cm 3 ~Approx. 0.375g / cm 3 , about 0.020g / cm 3 ~Approx. 0.350g / cm 3 , about 0.020g / cm 3 ~Approx. 0.325g / cm 3 , about 0.020g / cm 3 ~Approx. 0.300g / cm 3 , about 0.020g / cm 3 ~Approx. 0.275g / cm 3 , about 0.020g / cm 3 ~Approx. 0.250g / cm 3 , about 0.020g / cm 3 ~Approx. 0.225g / cm 3 , about 0.020g / cm 3 ~Approx. 0.200g / cm 3 , about 0.020g / cm 3 ~Approx. 0.175g / cm 3 , about 0.020g / cm 3 ~Approx. 0.150g / cm 3 , about 0.020g / cm 3 ~Approx. 0.125g / cm 3 , about 0.020g / cm 3 ~Approx. 0.100g / cm 3 , about 0.040g / cm 3 ~Approx. 0.475g / cm 3 , about 0.040g / cm 3 ~Approx. 0.450g / cm 3 , about 0.040g / cm 3 ~Approx. 0.425g / cm 3 , about 0.040g / cm 3 ~Approx. 0.400g / cm 3 , about 0.040g / cm 3 ~About 0.375g / cm 3 , about 0.040g / cm 3 ~About 0.350g / cm 3 , about 0.040g / cm 3 ~About 0.325g / cm 3 , about 0.040g / cm 3 ~About 0.300g / cm 3 , about 0.040g / cm 3 ~About 0.275g / cm 3 , about 0.040g / cm 3 ~About 0.250g / cm 3 , about 0.040g / cm 3 ~About 0.225g / cm 3 , about 0.040g / cm 3 ~About 0.200g / cm 3 , about 0.040g / cm 3 ~About 0.175g / cm 3 , about 0.040g / cm 3 ~About 0.150g / cm 3 , about 0.040g / cm 3 ~About 0.125g / cm 3 , about 0.040g / cm 3 ~About 0.100g / cm 3 , about 0.060g / cm 3 ~About 0.475g / cm 3 , about 0.060g / cm 3 ~About 0.450g / cm 3 , about 0.060g / cm 3 ~About 0.425g / cm 3 , about 0.060g / cm 3 ~About 0.400g / cm 3 , about 0.060g / cm 3 ~About 0.375g / cm 3 , about 0.060g / cm 3 ~About 0.350g / cm 3 , about 0.060g / cm 3 ~About 0.325g / cm 3 , about 0.060g / cm 3 ~About 0.300g / cm 3 , about 0.060g / cm 3 ~About 0.275g / cm 3 , about 0.060g / cm 3 ~Approx. 0.250g / cm 3 , about 0.060g / cm 3 ~Approx. 0.225g / cm 3 , about 0.060g / cm 3 ~Approx. 0.200g / cm 3 , about 0.060g / cm 3 ~Approx. 0.175g / cm 3 , about 0.060g / cm 3 ~Approx. 0.150g / cm 3 , about 0.060g / cm 3 ~Approx. 0.125g / cm 3 , or about 0.060 g / cm 3 ~Approx. 0.100g / cm 3 7. The composition of claim 6 having an average bulk density (not tapped density) of
8. The particles have a density of about 0.050 g / cm 3 ~Approx. 0.600g / cm 3 The composition of claim 1 having an average tap density of
9. The particles have a density of about 0.050 g / cm 3 ~Approx. 0.575g / cm 3 , about 0.050g / cm 3 ~Approx. 0.550g / cm 3 , about 0.050g / cm 3 ~Approx. 0.525g / cm 3 , about 0.050g / cm 3 ~Approx. 0.500g / cm 3 , about 0.050g / cm 3 ~Approx. 0.475g / cm 3 , about 0.050g / cm 3 ~Approx. 0.450g / cm 3 , about 0.050g / cm 3 ~Approx. 0.425g / cm 3 , about 0.050g / cm 3 ~Approx. 0.400g / cm 3 , about 0.050g / cm 3 ~Approx. 0.375g / cm 3 , about 0.050g / cm 3 ~Approx. 0.350g / cm 3 , about 0.050g / cm 3 ~Approx. 0.325g / cm 3 , about 0.050g / cm 3 ~Approx. 0.300g / cm 3 , about 0.050g / cm 3 ~Approx. 0.275g / cm 3 , about 0.050g / cm 3 ~Approx. 0.250g / cm 3 , about 0.050g / cm 3 ~Approx. 0.225g / cm 3 , about 0.050g / cm 3 ~Approx. 0.200g / cm 3 , about 0.050g / cm 3 ~Approx. 0.175g / cm 3 , about 0.050g / cm 3 ~Approx. 0.150g / cm 3 , about 0.050g / cm 3 ~Approx. 0.125g / cm 3 , about 0.075g / cm 3 ~Approx. 0.575g / cm 3 , about 0.075g / cm 3 ~About 0.550g / cm 3 , about 0.075g / cm 3 ~About 0.525g / cm 3 , about 0.075g / cm 3 ~About 0.500g / cm 3 , about 0.075g / cm 3 ~About 0.475g / cm 3 , about 0.075g / cm 3 ~About 0.450g / cm 3 , about 0.075g / cm 3 ~About 0.425g / cm 3 , about 0.075g / cm 3 ~About 0.400g / cm 3 , about 0.075g / cm 3 ~About 0.375g / cm 3 , about 0.075g / cm 3 ~About 0.350g / cm 3 , about 0.075g / cm 3 ~About 0.325g / cm 3 , about 0.075g / cm 3 ~About 0.300g / cm 3 , about 0.075g / cm 3 ~About 0.275g / cm 3 , about 0.075g / cm 3 ~About 0.250g / cm 3 , about 0.075g / cm 3 ~About 0.225g / cm 3 , about 0.075g / cm 3 ~About 0.200g / cm 3 , about 0.075g / cm 3 ~About 0.175g / cm 3 , about 0.075g / cm 3 ~About 0.150g / cm 3 , about 0.075g / cm 3 ~About 0.125g / cm 3 , about 0.100g / cm 3 ~About 0.575g / cm 3 , about 0.100g / cm 3 ~About 0.550g / cm 3 , about 0.100g / cm 3 ~About 0.525g / cm 3 , about 0.100g / cm 3 ~Approx. 0.500g / cm 3 , about 0.100g / cm 3 ~Approx. 0.475g / cm 3 , about 0.100g / cm 3 ~Approx. 0.450g / cm 3 , about 0.100g / cm 3 ~Approx. 0.425g / cm 3 , about 0.100g / cm 3 ~Approx. 0.400g / cm 3 , about 0.100g / cm 3 ~Approx. 0.375g / cm 3 , about 0.100g / cm 3 ~Approx. 0.350g / cm 3 , about 0.100g / cm 3 and about 0.325 g / cm 3 , about 0.100g / cm 3 ~Approx. 0.300g / cm 3 , about 0.100g / cm 3 ~Approx. 0.275g / cm 3 , about 0.100g / cm 3 ~Approx. 0.250g / cm 3 , about 0.100g / cm 3 ~Approx. 0.225g / cm 3 , about 0.100g / cm 3 ~Approx. 0.200g / cm 3 , about 0.100g / cm 3 ~Approx. 0.175g / cm 3 , about 0.100g / cm 3 ~Approx. 0.150g / cm 3 , or about 0.100 g / cm 3 ~Approx. 0.125g / cm 3 The composition of claim 8 having an average tap density of
10. 10. The composition of any one of claims 1 to 9, wherein the particles comprise at least 96%, 97%, 98%, 99%, or 100% niraparib, or a pharma- ceutically acceptable salt thereof.
11. 11. The composition of any one of claims 1 to 10, wherein the particles are uncoated and free of polymers, proteins, polyethoxylated castor oil, and polyethylene glycol glycerides composed of mono-, di- and triglycerides and mono- and diesters of polyethylene glycol.
12. 12. The composition of any one of claims 1 to 11, wherein the composition comprises a suspension further comprising a pharma- ceutically acceptable liquid carrier.
13. 13. The composition of any one of claims 1 to 12, further comprising one or more components selected from the group consisting of polysorbates, methylcellulose, polyvinylpyrrolidone, mannitol, and hydroxypropyl methylcellulose.
14. 11. The composition of any one of claims 1 to 10, wherein the suspension is aerosolized and the mass median aerodynamic diameter (MMAD) of the aerosol droplets of the suspension can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter.
15. (a) the composition is a dry powder composition, the dry powder composition does not include a carrier or any excipients, the dry powder composition is aerosolized, and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter; or (b) the composition is a dry powder composition, the dry powder composition comprising a pharma- ceutically acceptable dry powder carrier including one or more dry powder excipients, the dry powder composition being aerosolized, and the MMAD of the aerosolized dry powder composition can be any suitable diameter for use, such as from about 0.5 μm to about 6 μm in diameter; 12. The composition according to any one of claims 1 to 11.
16. 16. The composition of any one of claims 1 to 15, wherein the pharma- ceutically acceptable salt of niraparib comprises niraparib tosylate monohydrate.
17. 20. A method for treating a tumor, comprising administering to a subject having a tumor an effective amount of a composition described in any one of claims 1 to 16 to treat the tumor.
18. The tumor comprises a carcinoma, a breast tumor, a pancreatic tumor, a prostate tumor, a fallopian tube tumor, a peritoneal tumor, a bladder tumor, a lung tumor, a ovarian tumor, a gastrointestinal tumor, a testicular tumor, a cervical tumor, a head and neck tumor, an esophageal tumor, a mesothelioma, a brain tumor, a neuroblastoma, or a renal cell tumor; optionally, the subject has (i) progressive epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to initial platinum-based chemotherapy, (ii) recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in complete or partial response to platinum-based chemotherapy, or (iii) has been treated with three or more prior chemotherapy regimens, and the cancer is: harmful or suspected harmful BRCA mutations, or Genomic instability 18. The method of claim 17, wherein the patient has advanced ovarian, fallopian tube, or primary peritoneal cancer associated with homologous recombination repair deficient (HRD) positive status as defined by any of the following:
19. 19. The method of claim 17 or 18, further comprising administering to the subject an additional treatment including, but not limited to, an anthracycline, an antimetabolite, an alkylating agent (including but not limited to cisplatin), an alkaloid, a taxane (including but not limited to paclitaxel, docetaxel, cabazitaxel, and combinations thereof), and / or a topoisomerase inhibitor.
20. 20. The method of any one of claims 17 to 19, wherein the subject is a human subject.
21. 21. The method of any one of claims 17 to 20, wherein the composition is administered by intratumoral injection, peritumoral injection, intraperitoneal injection, pulmonary administration, or administered to the mammary fat pad.
22. 1. A method for producing niraparib particles, comprising: (a) (i) introducing into a nozzle inlet a solution comprising at least one solvent, including but not limited to ethanol, methanol, hexafluoroisopropanol (HFIP), or a combination thereof, and at least one solute, including niraparib or a pharma- ceutically acceptable salt thereof, and (ii) introducing a compressed fluid into an inlet of a container defining a pressurizable chamber; (b) passing the solution through a nozzle orifice into the pressurizable chamber to generate an outlet stream of atomized droplets, the nozzle orifice being located 2mm to 20mm from a sonic energy source located within the outlet stream, the sonic energy source generating sonic energy having an amplitude of 10% to 100% during the passage, and the nozzle orifice having a diameter of 20μm to 125μm; (c) contacting the atomized droplets with the compressed fluid to cause removal of the solvent from the atomized droplets to produce niraparib particles comprising at least 95% niraparib or a pharma- ceutically acceptable salt thereof, wherein the niraparib particles have a molecular weight of at least 5 mm. 2 / g specific surface area (SSA), optionally having an average particle size by volume distribution (Dv50) of about 1.0 microns to about 10.0 microns in diameter; The method of claim 1, wherein steps (a), (b), and (c) are carried out at a temperature and pressure that is supercritical of said compressed fluid.
23. (d) contacting the compound particles produced in step (c) with an anti-solvent to cause further removal of the solvent from the compound particles, wherein step (d) is carried out under a supercritical temperature and pressure of the anti-solvent.
23. The method of claim 22.
24. 24. The method of any one of claims 22 to 23, wherein the flow rate of the solution through the nozzle ranges from about 0.5 mL / min to about 30 mL / min.
25. 25. The method of any one of claims 22 to 24, wherein the sonic energy source comprises one of a sonic horn, a sonic probe, or a sonic plate.
26. 26. The method of any one of claims 22 to 25, wherein the sonic energy source has a frequency of about 18 kHz to about 22 kHz, or about 20 kHz.
27. (e) receiving the plurality of particles through the outlet of the pressurizable chamber; and (f) collecting the plurality of particles in a collection device.
27. The method of any one of claims 22 to 26, further comprising:
28. 28. The method of any one of claims 22 to 27, wherein the compressed fluid is supercritical carbon dioxide.
29. 29. The method of any one of claims 22 to 28, wherein the anti-solvent is supercritical carbon dioxide.
30. 30. The method of any one of claims 22 to 29, carried out at 31.1°C to about 60°C and at about 1071 psi to about 1800 psi.
31. The particles are at least 10 m 2 31. The method of any one of claims 22 to 30, having an SSA of 0.01 to 0.01 g.
32. 32. Niraparib particles prepared by the method of any one of claims 22 to 31.
